Goseki histological grading of gastric cancer is an important predictor of outcome

I G Martin, M F Dixon, H Sue-Ling, A T R Axon, D Johnston

Abstract
TNM (tumour, node, metastases) staging has thus far been the most important guide to prognosis in patients with gastric cancer. Histological grading, in contrast, has not provided any additional information. Recently a novel grading system based on tubular differentiation and mucus production has been proposed, which was correlated with patterns of tumour spread found at necropsy. This study set out to assess its value as a determinant of survival after gastric resection. In a consecutive series of 211 patients who had potentially curative resection for gastric cancer, five histological grading systems were assessed: the Lauren type, the WHO type, degree of differentiation, the type of tumour border, and the lymphocytic response to the tumour and compared with the Goseki grading (I-IV). When T and N stage were taken into account, using Cox’s proportional hazards model, only the Goseki grading added further to the ability to predict survival. The proportional hazards ratios were: node negative v node positive 6-5 T1 v T3 2-45; Goseki I v Goseki IV 3-1. Five year survival of patients with mucus rich (Goseki II and IV) T3 tumours was significantly worse than that of patients with mucus poor (Goseki I and III) T3 tumours (18% v 53%, p<0.003). Goseki grading identifies subgroups of patients with a poorer prognosis than is predicted by TNM staging alone. It could prove useful in the selection of patients for adjuvant therapy after potentially curative resection for gastric cancer.

(Gut 1994; 35: 758–763)

It has been recognised for some time that gastric cancer exhibits wide variation in its morphology and behaviour. To date, however, the correlation between its morphological characteristics and clinical behaviour has been poor. Most clinicians have accepted that the morphology of gastric cancers is of limited, if any, value in determining clinical outcome. The TNM (tumour, node, metastases) staging system for gastric cancer is widely used, provides useful prognostic information, and is the most important clinical method for staging adenocarcinoma of the stomach. It is widely used in many clinical settings without reference to histological morphology because the latter is felt to be of little practical importance.

Because of the wide variation in the morphological characteristics of gastric cancer, numerous histological classification systems have been proposed. Jarvii2 suggested that the histological origin of gastric cancer was within islands of intestinal metaplasia, giving rise to the Lauren classification of gastric cancers into so-called intestinal or diffuse types. Gastric cancer has also been classified according to the degree of differentiation exhibited by the tumour.3 4 Ming5 proposed a classification based on the histological appearance of the tumour border (infiltrative or expansive). Finally, the WHO proposed a morphological categorisation based on histological appearance and type.6 Despite initial enthusiasm, however, for each of these histological classifications of gastric cancer, none has yet added to the TNM staging system in the ability to predict outcome.

Goseki et al7 have recently proposed a novel histological method for classifying gastric cancer based on intracellular mucus production and the degree of tubular differentiation. Four grades of tumour were proposed (Fig 1): group I: tubules well differentiated, intracellular mucus poor; group II: tubules well differentiated, intracellular mucus rich; group III: tubules poorly differentiated, intracellular mucus poor; group IV: tubules poorly differentiated, intracellular mucus rich.

The authors compared this new histological system to the pattern of metastatic spread found at postmortem examination, but its relation to clinical outcome (five year survival) has not yet been reported. We describe here the relation between the Goseki grading system, other histological classification systems, TNM staging, and clinical outcome in a consecutive series of patients who had received potentially curative resection for gastric cancer.

Patients
Between 1969 and 1990, 517 patients presented to the academic department of surgery with adenocarcinoma of the stomach, of whom 211 (41%) received potentially curative resection (defined as removal of all macroscopic tumour, with clear resection margins). Most were radical (R0) resections, with extensive lymphadenectomy.8 Twenty seven of these 211 patients had intramucosal carcinoma only. These patients were excluded from further analysis because the behaviour of these lesions is well known and any additional prognostic information would be marginal, and in some insufficient pathological material was available for accurate evaluation. In three patients the
Goseki histological grading of gastric cancer is an important predictor of outcome

Figure 1: Haematoxylin and eosin (upper panels) and alcian blue PAS stained sections (lower panels) illustrating typical examples of the four Goseki grades: (A) a tumour showing good tubulopapillary differentiation but a poor intracytoplasmic mucin content – grade I; (B) good tubulopapillary differentiation and plentiful intracytoplasmic mucin – grade II; (C) poor tubular differentiation and poor mucin content – grade III; (D) poor tubular differentiation but rich mucin content – grade IV

pathological specimen and slides were not available for study. Thus 181 patients were left for analysis. Table I shows the details of these 181 patients.

Methods

The histological specimens were classified by one of the authors (MFD), without knowledge of the clinical outcome, according to the following systems: Goseki grade (I–IV); Lauren classification (intestinal, mixed, diffuse); WHO classification; Ming classification of the type of border (expansive, infiltrative); degree of differentiation (well, moderate, poor); lymphocyte infiltration of tumour (graded 0–3; no lymphocytes, small numbers, moderate numbers, and numerous lymphocytes).

The tumours were staged using the Unified 1987 TNM system for gastric cancer. Patients were reviewed every six months at a special gastric follow up clinic. The cause of death in each case was determined from our own records or those of the Yorkshire
TABLE I  Details of the 181 patients who received potentially curative resection for gastric cancer

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Goseki I</th>
<th>Goseki II</th>
<th>Goseki III</th>
<th>Goseki IV</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean)</td>
<td>68-6</td>
<td>67-8</td>
<td>66-3</td>
<td>66-9</td>
<td>66.8</td>
</tr>
<tr>
<td>Male:female</td>
<td>38:16</td>
<td>17:10</td>
<td>33:17</td>
<td>30:20</td>
<td>118:63</td>
</tr>
<tr>
<td>Operation type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal gastrectomy</td>
<td>23</td>
<td>15</td>
<td>17</td>
<td>29</td>
<td>84</td>
</tr>
<tr>
<td>Total gastrectomy</td>
<td>27</td>
<td>10</td>
<td>29</td>
<td>18</td>
<td>84</td>
</tr>
<tr>
<td>Oesophagogastrectomy</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>Tumour stage</td>
<td>I</td>
<td>II</td>
<td>III</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>7</td>
<td>17</td>
<td>17</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>8</td>
<td>11</td>
<td>10</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>12</td>
<td>22</td>
<td>23</td>
<td>76</td>
</tr>
</tbody>
</table>

TABLE II  The influence of TNM staging and histological grading on survival after potentially curative resection for gastric carcinoma

<table>
<thead>
<tr>
<th>Category</th>
<th>No of patients</th>
<th>Five year survival Kaplan and Meier plot (%)</th>
<th>Significance of log rank test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unified TNM staging:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>35</td>
<td>97</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>T2</td>
<td>60</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>83</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>81</td>
<td>98</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>N1</td>
<td>63</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>37</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Goseki grade:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goseki I</td>
<td>54</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Goseki II</td>
<td>27</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Goseki III</td>
<td>50</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Goseki IV</td>
<td>50</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Lauren classification:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestinal</td>
<td>134</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td>Diffuse</td>
<td>36</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>WHO classification:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td>11</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>Tubular</td>
<td>115</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Signet ring</td>
<td>9</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td>19</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Unclassified</td>
<td>27</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Grade of tumour:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>32</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>54</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>95</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Ming's classification:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expansive border</td>
<td>42</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Infiltrative border</td>
<td>139</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Lymphocytic infiltration:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No lymphocytes</td>
<td>83</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes 1</td>
<td>50</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes 2</td>
<td>34</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes 3</td>
<td>14</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

Regional Cancer Registry. Follow up was complete in all but one patient. Median follow up was 5-1 years. Survival was calculated by the life table method of Kaplan and Meier.9 Survival curves were compared statistically using the log rank test.10 The comparative importance of various factors in determining survival was calculated by means of Cox's proportional hazards model.11

Results

HISTOLOGICAL GRADING AND SURVIVAL

Among the 181 patients who had potentially curative resection for gastric cancer, operative mortality was 6%. Cumulative survival, calculated by life table analysis, after exclusion of operative deaths, was 60% at five years and 55% at 10 years.

Table II summarises the relation between lymph node involvement (N), depth of tumour penetration (T), and survival. Five year survival in patients without lymph node metastasis was 88%; with lymph node metastasis, 37% (p<0.001). Likewise, five year survival of patients with tumour confined to the wall of the stomach (T1 and T2) was 82%, but when the tumour had penetrated through the serosa (T3), survival was only 36% (p<0.001).

Table II shows the effects of the various histological grading systems on survival, irrespective of T and N staging. The Goseki grade, Lauren type, and grade of tumour were found to be important predictors of outcome when analysed without account of T and N stage. The WHO classification was not designed to predict clinical outcome and most tumours fall in just one category (tubular); it is therefore inappropriate to apply statistical tests across the various categories.

To find out if any of these histological grading systems added further to the T and N staging in predicting survival, the results were analysed by means of Cox's proportional hazards model. The histological factors that seemed to be independently associated with survival after potentially curative resection for gastric cancer (see Table II), were placed in the model together with T and N stage. After the first analysis, non-contributory factors (p>0.05) were removed in a stepwise fashion. The final model contained only three factors: nodal involvement (N stage), depth of tumour penetration (T stage), and the Goseki grade of the tumour. Table III shows the results of this analysis.

Figure 2 shows the relation between the Goseki histological grading system and clinical outcome. Five year survival was 80% in patients with Goseki I tumours (tubules well differentiated, intracellular mucus poor) but only 46% in patients with Goseki IV tumours (tubules poorly differentiated, intracellular mucus rich) (p<0.001).

Of the two components of the Goseki system, namely tubular differentiation and intracellular mucus production, mucus production was found to be the more important determinant of clinical outcome. Five year survival of patients with tumours that showed good tubular differentiation (Goseki I and II) was 69%, compared with 54% in patients with tumours that showed poor tubular differentiation (Goseki III and IV) (p<0.05). In contrast, five year survival of patients with mucus poor tumours (Goseki I and III) was 71%, but only 45% in patients with mucus rich tumours (Goseki II and IV) (p<0.001). The effect of mucus production on survival was also found to be independent of T and N staging (Figs 3 and 4).

TABLE III  Results of the application of Cox's proportional hazards model

<table>
<thead>
<tr>
<th>Parameter</th>
<th>β</th>
<th>σ</th>
<th>Example of hazards ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nodal involvement N0, N1, N2</td>
<td>1.41</td>
<td>1.41</td>
<td>N0 v N2 12.8</td>
</tr>
<tr>
<td>Goseki grade I, II, III, IV</td>
<td>0.45</td>
<td>0.57</td>
<td>T1 v T2 1.45</td>
</tr>
<tr>
<td>Goseki I v IV 3-1</td>
<td>0.38</td>
<td>1.46</td>
<td></td>
</tr>
</tbody>
</table>

Discussion

The American pathologist Stout commented in 1953 that 'histological classification was
Goseki et al based their system on two features of gastric cancer: the structural features of tubular differentiation and the functional state of mucus production. They stated that few would challenge the use of tubular differentiation, but believed that the use of mucus production would be questioned by others. We have shown, however, that degree of mucus production by the tumour is of greater importance than tubular differentiation in the assessment of prognosis. We therefore support Goseki’s opinion that accumulation of mucus does not merely represent the absence of a suitable tubular structure for mucus excretion.

In Goseki’s original paper the distribution of tumours among the four grades was different to that in our series with fewer patients in Goseki grade I and proportionately more in Goseki grade IV. Although the reason for this is not absolutely clear there are two possible explanations; firstly the fact that Goseki’s study was carried out on necropsy material and hence more likely to include patients with aggressive tumours and secondly it is well recognised that there is a higher proportion of diffuse poorly differentiated tumours in Japan.

The Lauren classification has been one of the most widely applied histological grading systems, particularly in epidemiological studies. While this system may have its applications in such broad epidemiological studies, there is no evidence that the Lauren classification can add to the prognostic information that is provided by TNM staging. In the original description of the Lauren system there was an eight per cent difference in survival between the intestinal and diffuse groups at three years (43% vs 35% respectively). When the Lauren classification was applied, however, by other authors to larger series of patients, no difference in five year survival was found. A further disadvantage of the Lauren system is that between 10 and 20% of cases remain unclassified. Ming’s system, which is based on tumour infiltration, has the advantage over the Lauren system that all cases can be classified, but again there is no evidence that it is of prognostic value. While the WHO classification is widely used, it has several drawbacks; for example, it fails to classify a significant proportion of tumours and many tumours straddle two or more categories. Again, there is little evidence that the WHO classification is important in determining clinical outcome, not unsurprising when it is realised that this was not the reason for the formulation of this system.

There is no evidence in published works that any of the other histological grading systems is useful in predicting outcome, once tumour spread (TNM stage) has been considered, a view that is supported by our findings. It was disappointing to find that the degree of lymphocyte infiltration of the tumour had no apparent effect on survival. It would be satisfying if it could be shown that the body’s own immune response could be shown to have an effect on clinical outcome. This is in contrast
with the report of Scachenmayr, in 1979 who stated that stromal reaction had a beneficial effect upon survival, although the evidence for this was weak,\(^1\) and again little account was taken of TNM stage.

Why should the differences in histological appearance of gastric cancer emphasised by Goseki affect prognosis? The finding that the degree of tubular differentiation affects prognosis should come as no surprise, but what is more interesting is that the amount of mucus produced by these gastric cancers should have such a profound effect upon clinical outcome. Mucus production has a greater impact on survival than the degree of tubular differentiation and is independent of the degree of tubular differentiation. We are not the first to describe the apparently better prognosis of tumours containing little mucus. Paile in 1971 showed a significantly poorer five year survival in patients with tumours rich in mucus.\(^1\) In that study, however, little account was taken of tumour stage and no distinction was made between intra and extracellular mucus. Two studies have commented on the variable behaviour of so called mucoid gastric carcinomas. Both Brander\(^1\)\(^\text{1}\) and Ishii\(^1\)\(^\text{18}\) showed that while signet ring carcinomas, high in intracellular mucus, behaved in a very aggressive fashion, well differentiated tumours sitting in lakes of extracellular mucus seemed to progress slowly, supporting the belief of Goseki that it is intracellular mucus that is the important determinant of tumour behaviour.

It is not clear why tumours that are rich in intracellular mucus should have a worse prognosis than tumours with little intracellular mucus. There is some evidence from Goseki’s paper that the tumours rich in mucus were associated with greater numbers of lymph node metastasis than those containing little mucus, although this must be interpreted with caution given that it was a postmortem study. One research group has shown chromosome I abnormalities in some patients with gastric cancer,\(^1\)\(^\text{19}\) in an area known to code for mucus production. Whether tumours that are rich in intracellular mucus have different underlying molecular biological abnormalities compared with tumours poor in mucus remains to be determined.

We would propose that the Goseki classification, if it is to be widely adopted, should be changed, to transpose grades II and III, so as to reflect the greater importance of mucus production on survival. Thus, our proposed modification of the system would be as follows: group I: intracellular mucus poor, tubules well differentiated; group II: intracellular mucus poor, tubules poorly differentiated; group III: intracellular mucus rich, tubules well differentiated; group IV: intracellular mucus rich, tubules poorly differentiated.

It is not clear whether these findings are of any clinical relevance. At present, we feel that this histological grading system could not be applied to preoperative endoscopic biopsy specimens with any degree of accuracy, because of the small samples of tissue available, although we have not formally tested this ourselves. Nevertheless, we think that the Goseki classification, or our proposed modification of it, is possibly of use in helping to select patients for adjuvant treatment after surgical resection because it identifies groups of patients in whom the prognosis is significantly worse than that predicted by TNM staging alone. We are conscious, however, that the analysis presented here is retrospective and based on one pathologist’s assessment of the histology. Whether this staging system is valid when tested prospectively and whether it is both repeatable and reproducible remains to be assessed.

In summary, we have shown that the new histological grading system proposed by Goseki provides a more accurate prognosis in patients with gastric carcinoma when added to the TNM staging system alone. In this, it differs from all other histological grading systems previously described. Mucus production by the tumour was found to be more important in determining patients’ survival than the degree of tubular differentiation. If the Goseki system is to be widely adopted, we would propose that grades II and III be transposed to place greater emphasis on the prognostic importance of mucus production.

---


---

**Figure 4:** Survival after potentially curative resection for 63 patients with N1 gastric cancer according to mucus production.

![Graph showing survival rates for different types of mucus production](https://example.com/graph)
Goseki histological grading of gastric cancer is an important predictor of outcome.


